[Statines for all or individualized lipid lowering therapy?].
Parhofer
K
K
Klinikum der Universität München-Grosshadern. klaus.parhofer@med.uni-muenchen.de
D003362:Cost-Benefit Analysis; D016527:Drug Costs / Q000706:statistics & numerical data; D019317:Evidence-Based Medicine; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D006949:Hyperlipidemias / Q000188:drug therapy* / Q000191:economics; D000960:Hypolipidemic Agents / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D009203:Myocardial Infarction / Q000191:economics / Q000517:prevention & control; D016032:Randomized Controlled Trials as Topic; D020521:Stroke / Q000191:economics / Q000517:prevention & control; D016896:Treatment Outcome
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents